Medical Oncology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain.
Clin Transl Oncol. 2011 May;13(5):307-14. doi: 10.1007/s12094-011-0659-0.
Uterine sarcomas comprise a heterogeneous group of diseases with different pathology appearance, clinical course and natural history. They account for only 3% of all uterine malignancies. The rarity of this entity has precluded the development of large and well designed randomised clinical trials, and for this reason the current management of some aspects of this disease is based on trials or retrospective studies with a low level of evidence. For this reason, it is mandatory to develop international cooperation to carry out clinically relevant clinical trials in this field. Accordingly, based on the relative rarity of these tumours, management of these patients should be centralised and must be performed by a multidisciplinary team including gynaecologic oncologist, pathologist, medical oncologist and radiation oncologist. This review focuses on the most accepted evidence about the management of uterine sarcomas. Although carcinosarcoma has been recently excluded from the sarcoma classification, some aspects of its treatment have also been included in this review.
子宫肉瘤是一组具有不同病理学表现、临床过程和自然史的异质性疾病。它们仅占所有子宫恶性肿瘤的 3%。这种疾病的罕见性使得无法开展大型和精心设计的随机临床试验，因此，目前对这种疾病某些方面的治疗是基于试验或低证据水平的回顾性研究。出于这个原因，必须开展国际合作，在这一领域开展有临床意义的临床试验。因此，基于这些肿瘤的相对罕见性，这些患者的治疗应集中进行，必须由妇科肿瘤学家、病理学家、肿瘤内科医生和放射肿瘤学家组成的多学科团队来进行。本综述重点介绍了关于子宫肉瘤治疗的最可接受的证据。尽管癌肉瘤最近已被排除在肉瘤分类之外，但其中一些治疗方面也包括在本综述中。
